HYPOXIA and Augmentin


HYPOXIA Symptoms and Causes

A coma is a deep state of unconsciousness. An individual in a coma is alive but unable to move or respond to his or her environment. Coma may occur as a complication of an underlying illness, or as a result of injuries, such as brain injury.

A coma rarely lasts more than 2 to 4 weeks. The outcome for coma depends on the cause, severity, and site of the damage. People may come out of a coma with physical, intellectual, and psychological problems. Some people may remain in a coma for years or even decades. For those people, the most common cause of death is infection, such as pneumonia.

NIH: National Institute of Neurological Disorders and Stroke

Check out the latest treatments for HYPOXIA

HYPOXIA treatment research studies

Augmentin clinical trials, surveys and public health registries

Find Drug Side Effect reports

Augmentin Side Effects

Diarrhoea (341)
Pruritus (324)
Rash (236)
Pyrexia (227)
Jaundice (205)
Erythema (198)
Alanine Aminotransferase Increased (194)
Dyspnoea (186)
Urticaria (180)
Anaphylactic Shock (179)
Vomiting (173)
Aspartate Aminotransferase Increased (168)
Blood Alkaline Phosphatase Increased (164)
Nausea (152)
Abdominal Pain (145)
Hypotension (136)
Cholestasis (136)
Hepatitis Cholestatic (134)
Gamma-glutamyltransferase Increased (130)
Malaise (119)
Hypersensitivity (113)
Blood Bilirubin Increased (108)
Rash Maculo-papular (104)
Face Oedema (103)
Asthenia (98)
Hepatitis (96)
Toxic Skin Eruption (92)
Abdominal Pain Upper (89)
Anaphylactic Reaction (86)
Renal Failure Acute (79)
Chromaturia (78)
Oedema Peripheral (74)
Eosinophilia (74)
Purpura (73)
Angioedema (73)
Dizziness (71)
Anaemia (69)
Bronchospasm (69)
International Normalised Ratio Increased (69)
Thrombocytopenia (67)
Tachycardia (66)
Rash Erythematous (65)
Inflammation (63)
Oedema (63)
Fatigue (61)
Pain (54)
Dehydration (54)
Anorexia (53)
Death (53)
Blood Pressure Decreased (53)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Recent Reviews

3rd day on augmentin and i'm getting chest pain didn't think it could be related and really bad nausea when I took it this morning. They don't list that as a side effect.

And it has blister now ,,,im afraid i dont know what to do,,,

Augmentin 625 ; ive been on it for 2 days,feeling sick and central chest pain [ like bad heartburn]

Augmentin 625: 2x a day I've been on it for 2 days. Experienced unexplained joint pains and swelling of my hands, feet & face. Can see flashes on my left eye on the 2nd day. Have also noticed that I always want to eat.

Buna imi poate spune si mie cineva ce contine augumentinu ca eu sunt alergica la amoxicilina

Can augmentine 625 mg twice daily for five days cause as a side effect Hyperthermia

Doctor had me take amoxicillin 500mg because of sinus infection. I toke 4x500mg for 10days. It cleared up the infection but I have had acute gout attacks for over a month. my feet/hands/wrists/knees have developed terrible pain to the point that I co

Due to elevated liver enzyme levels and an elevated ANA, my previous doctor gave me a diagnosis of autoimmune hepatitis. After reviewing my charts, my current doctor believes that it was an autoimmune response to 3 back-to-back courses of amoxicillin

Has anyone developed boday aches anda fever following only a second dose? I was perfectly fine,no fever just abronchial inflamation. feel horrible!

I am on it for second day too. Only side effects I have had was diarrhea, slight headache, and for some reason I have a herpes blister on my hand, which is where the virus lies dormant (until now). I am hoping the blister will go away right after I g

Do steroids cause Hypoxia? The reason I ask this question is because when my wife, who has a Lung condition, exercises after consuming 15 mg Prednisone, she experiences Hypoxia. It does not happen on other occasions. Could the steroid cause this Hypo

HYPOXIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Neuropsychological Sleep Physical Exercise Hypoxia
Condition: Hypoxia
Outcome Measure:
2 Recruiting Intermittent Hypoxia 2: Cardiovascular and Metabolism
Conditions: Hypoxia;   Sleep Apnea;   Obstructive Sleep Apnea
Interventions: Drug: Placebo;   Drug: Valsartan;   Drug: Amlodipine
Outcome Measures: Change in sympathetic activity;   Measure of adrenergic, inflammatory and metabolic markers in adipose tissues by chronic intermittent Hypoxia versus placebo in healthy nonobese subjects.;   Measure variations in parameters of inflammation in adipose tissue by chronic intermittent Hypoxia versus placebo in healthy nonobese subjects.;   Measure of metabolic aspects of the OGTT test.;   Measure the activation of systemic inflammation by chronic HI versus placebo in healthy nonobese subjects. The systemic inflammation will be assessed in non-stress and during the OGTT.;   Assessing markers implicated in the pathophysiology of chronic metabolic diseases after HI versus placebo in healthy nonobese subjects during OGTT.;   Change in vascular responsivness;   Change in Sympathetic and vascular determinant of Blood pressure
3 Recruiting Study of Intratumoral Hypoxia Using Pre-operative Administration of Pimonidazole
Condition: Pancreatic Cancer
Intervention: Drug: Pimonidazole hydrochloride
Outcome Measures: characterization of intratumoral Hypoxia in pancreatic cancer;   correlation of intratumoral Hypoxia with patient survival rate;   correlation of Hypoxia with molecular markers;   to assess utility of circulating osteopontin and miR-210 for identifying Hypoxia
4 Recruiting A Study Using 18F-FAZA and PET Scans to Study Hypoxia in Pancreatic Cancer
Conditions: Pancreatic Cancer;   Hypoxia
Outcome Measures: Measure the Hypoxia level in Patients with Pancreatic Cancer using Positron Emission Tomography (PET) with 18F-Fluoroazomycin Arabinoside (18F-FAZA).;   Correlate FAZA PET uptake in pancreatic cancer with the extension of the disease.;   Correlate FAZA PET uptake in pancreatic cancer with CA 19-9 levels.;   Correlate FAZA PET uptake in pancreatic cancer with tumor response.;   Correlate FAZA PET uptake in pancreatic cancer with patient disease-free survival (DFS).;   Compare the pattern of FAZA uptake in different tumor sites (eg., lymph node metastases and liver metastasis).;   Determine the feasibility of using dynamic and static PET imaging of FAZA uptake in patients with pancreatic cancer.
5 Recruiting RHYTHM-I: Investigating Hypoxia in Rectal Tumours
Condition: Hypoxia in Rectal Cancer
Interventions: Other: Pimonidazole;   Other: F-MISO scan
Outcome Measures: Group A FMISO-PET derived hypoxic volumes;   Group B Percentage change in FMISO-PET SUVmax and uptake volume;   Hypoxia gene microarray read outs from biopsies;   FMISO-PET SUVmax;   pCT derived blood flow parameters
6 Recruiting Effects of Oxygen Status on Endotoxemia Induced Inflammation and Hypoxia Inducible Factor-1α
Conditions: Hypoxia;   Normoxia;   Hyperoxia
Intervention: Drug: Lipopolysaccharide
Outcome Measures: Plasma TNF-alpha concentration following LPS administration;   Hypoxia Inducible Factor 1 alpha in circulating leukocytes;   Hypoxia Inducible Factor mRNA and anti Hypoxia Inducible Factor mRNA in circulating leukocytes;   Reactive Oxygen Species in circulating leukocytes;   Phagocytic function of circulating leukocytes;   cytokine production after ex vivo stimulation of leukocytes;   circulating cytokines (including but not limited to IL-6, IL-10, IL-1RA);   Hemodynamic parameters;   ventilatory response;   adenosine metabolism;   alkaline phosphatase;   cognitive function;   Hepcidin and iron parameters;   catecholamines and cortisol;   Neutrophilic function;   body temperature;   oxygen saturation and arterial blood gas;   subjective symptom scores;   high sensitive troponine;   iFABP;   brain specific proteins;   endocan;   downstream targets of HIF;   heart rate variability;   kidney injury markers in plasma and urine;   microbiome in feces;   markers of immunoparalysis;   measures of coagulation and plateletfunction;   meausures of coagulation and fibrinolysis
7 Recruiting Effects of O2 and/or CO2 Inhalation on Rest and Exercise Pulmonary Hemodynamic
Conditions: Pulmonary Vascular Sensibility in Hypoxia;   Hypercapnia;   Hypoxia and Hypercapnia
Interventions: Device: Hypercapnia inhalation (Altitrainer NP 190);   Device: Hypoxia and hypercapnia (Altitrainer NP 190);   Device: Hypoxia inhalation (Altitrainer NP 190)
Outcome Measures: Systolic Artery Pulmonary Pressure(sPAP) (echocardiography, Cardiac output (impedancemetry), Cardiorespiratory parameters;   Dyspnea and muscle leg discomfort using a Borg Scale
8 Unknown  Scalp Sampling for Fetal Surveillance
Condition: Fetal Hypoxia
Intervention: Other: Fetal scalp blood scalp, amniotic fluid, maternal blood and umbilical cord sampling
Outcome Measures: Hypoxia;   Subacute Hypoxia
9 Unknown  Effects of Expiratory Pressure on Arterial Oxygenation During Hypoxia
Condition: Hypoxia
Intervention: Device: threshold PEEP
Outcome Measures: SpO2;   peripheral HbO2/DeoxyHb;   cardiac output;   pattern of breathing (fR, VT, PETCO2)
10 Recruiting Evaluation of Hypoxia by PET With F-Miso in Radiation Therapy of Prostate Cancer
Condition: Prostate Adenocarcinoma
Intervention: Drug: 18-F-MISO
Outcome Measures: To characterize changes in tumor Hypoxia (PET with 18F-MISO) during radiation therapy of prostate cancer.;   To compare Hypoxia imaging (PET with 18F-MISO) with anatomical imaging (PET with 18F-choline) to study the feasibility of a tailored treatment.
11 Recruiting Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Conditions: Infant, Newborn;   Hypoxia, Brain;   Hypoxia-Ischemia, Brain;   Encephalopathy, Hypoxic-Ischemic;   Hypoxic-Ischemic Encephalopathy;   Ischemic-Hypoxic Encephalopathy
Interventions: Procedure: Hypothermia;   Procedure: Normothermic Control
Outcome Measures: Death or moderate or severe disability;   Number of deaths in the NICU and following discharge;   Number of infants with moderate and severe disability;   Number of infants with mild, moderate and severe disability;   Number of infants with any disability based on level of encephalopathy at randomization;   Number of infants with non-CNS organ system dysfunction;   Number of infants with a DNR order;   Number of infants with a DNR order and support is withdrawn;   Number of infants with a DNR order and either die or survive;   Number of infants with neonatal seizures, with and without EEG abnormalities
12 Not yet recruiting The Mechanisms of Diameter Changes in Retinal Vessels During Hypoxia
Condition: Retinal Hypoxia
Interventions: Drug: COX-inhibitor;   Drug: Nitroglycerin;   Drug: COX-inhibitor + Nitroglycerin
Outcome Measure: Diameter changes of retinal vessels
13 Unknown  The Diagnosis of Occult Deep Vein Thrombosis of the Lower Extremities in Patients Presenting With Hypoxia
Condition: Hypoxia
Intervention: Device: Ultrasound compression of femoral and popliteal veins
Outcome Measure:
14 Recruiting Predictive Assays In Cervix Cancer
Condition: Cervical Cancer
Intervention: Other: Tumour Biopsies and Blood Sampling
Outcome Measures: To understand the mechanisms by which Hypoxia and IFP influence disease progression, and response to radiotherapy, chemotherapy and other novel biologically-targeted therapies in patients with cervix cancer.;   To determine if tissue biomarkers of Hypoxia are independent prognostic factors for relapse and survival in patients with cervix cancer.;   To determine if plasma biomarkers of Hypoxia are independent prognostic factors for relapse and survival in patients with cervix cancer.;   To assess the heterogeneity of tissue biomarkers of Hypoxia in multiple biopsies from cervix cancers.
15 Recruiting Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer
Conditions: Ovarian Cancer;   Ovarian Neoplasms
Interventions: Drug: 18F-EF5 PET/CT scan;   Procedure: Optional biopsy
Outcome Measures: Ability of 18F-EF5 to detect areas of tumour Hypoxia in clear cell tumours of the ovary;   Correlate cellular markers of Hypoxia and autophagy to the results of the 18F-EF5 PET/CT scans.
16 Recruiting BiHiVE2 Study. The Investigation and Validation of Predictive Biomarkers in Hypoxic-ischaemic Encephalopathy.
Conditions: Hypoxic Ischaemic Encephalopathy (HIE);   Asphyxia
Outcome Measures: EEG confirmed hypoxic-ischaemic brain injury in the first 72 hours of life;   Neurodevelopmental outcome at 2 years of age assessed using BSID III
17 Recruiting FMISO-PET in Brain Tumors and SCS Effect
Condition: Malignant Glioma
Interventions: Drug: 18F-FMISO;   Procedure: PET without SCS;   Device: SCS;   Procedure: PET without/with SCS;   Radiation: Radiotherapy;   Drug: Temozolomide
Outcome Measures: Tumor Hypoxia measurement using 18F-FMISO-PET (hypoxic volume and tumor/muscle ratio). Baseline measurement.;   Change from baseline tumor Hypoxia using 18F-FMISO-PET (hypoxic volume and tumor/muscle ratio) during SCS.;   Correlation between 18F-FMISO-PET values and pathological tumor parameters;   Correlation with Karnofsky scale.;   Correlation with the ECOG (Eastern Cooperative Oncology Group) performance status scale;   Correlation with the Quality of Life Questionnaire QLQ-C30 (EORTC);   Overall survival.;   Radiological response to treatment;   Radiological location of tumor relapse or progression
18 Recruiting Cervix Hypoxia FAZA
Condition: Cervix Cancer
Intervention: Procedure: 18F-Fluoroazomycin Arabinoside (18F-FAZA)
Outcome Measure: Number of patients treated with the PET tracer FAZA to image primary tumor Hypoxia in patients with cervix cancer prior to treatment with radiotherapy and concurrent cisplatin chemotherapy
19 Recruiting Migraine With Aura Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow by Hypoxia
Conditions: Headache;   Migraine;   Aura
Interventions: Other: Hypoxia;   Other: Placebo
Outcome Measures: Headache and aura;   artery circumference;   Cerebral blood flow;   Resting state functional connectivity
20 Unknown  Training in Hypoxia to Prevent Acute Mountain Sickness
Conditions: Acute Mountain Sickness;   Healthy
Interventions: Other: Hypoxia;   Other: normoxia
Outcome Measures: Incidence of acute mountain sickness;   Severity of acute mountain sickness